MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH)

Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?)
Ratings Breakdown: 10 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $23.18 (476.66% upside)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016WedbushReiterated RatingNeutral$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2016GabelliReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2016Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageMarket Perform$8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015SunTrustUpgradeNeutral -> Buy$12.00 -> $21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015GuggenheimLower Price TargetBuy$60.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Robert W. BairdDowngradeOutperform -> Neutral$41.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Cantor FitzgeraldDowngradeBuy -> Hold$50.00 -> $11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015NomuraDowngradeBuy -> Neutral$54.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Stifel NicolausDowngradeBuy -> Hold$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/27/2014 forward)
Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015($0.54)($0.69)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.46)($0.41)($0.44)
Q2 20162($0.48)($0.44)($0.46)
Q3 20162($0.54)($0.47)($0.51)
Q4 20162($0.59)($0.47)($0.53)
Q1 20171($0.56)($0.56)($0.56)
Q2 20171($0.58)($0.58)($0.58)
Q3 20171($0.59)($0.59)($0.59)
Q4 20171($0.53)($0.53)($0.53)
(Data provided by Zacks Investment Research)
Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
DateHeadline
06/26/16 07:34 AMCovering the Bases on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH): Where is the Stock Going? - Press Telegraph
06/23/16 07:42 PMHynes Keller & Hernandez, LLC Announces Investigation of Tetraphase Pharmaceuticals Inc. (TTPH) - PR Newswire (press release)
06/23/16 12:16 PMHynes Keller & Hernandez, LLC Announces Investigation of Tetraphase Pharmaceuticals Inc. (TTPH) - [PR Newswire] - NEW YORK, June 23, 2016 /PRNewswire/ -- Hynes Keller & Hernandez, LLC is investigating potential claims against the Board of Directors of Tetraphase Pharmaceuticals Inc. ("Tetraphase" or the ...
06/23/16 09:29 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Momentum Hits EXTREME Weakness - CML News
06/21/16 06:26 PMTetraphase Pharmaceuticals : Presents Antibiotics Pipeline Data at ASM Microbe 2016
06/21/16 07:37 AMTetraphase Pharma (TTPH) Presents Data from IGNITE1 and IGNITE2 at ASM Conference
06/20/16 06:29 PMTetraphase Pharma (TTPH) Presents Data from IGNITE1 and IGNITE2 at ASM Conference - StreetInsider.com
06/20/16 03:29 PMTetraphase Pharmaceuticals Presents Antibiotics Pipeline Data at ASM Microbe 2016 - [at noodls] - WATERTOWN, Mass., June 20, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
06/16/16 07:06 PMTetraphase Pharmaceuticals Inc. (TTPH) Jumps 5.01% on June 16 - Equities.com
06/15/16 07:19 AMTetraphase Pharmaceuticals to Present at 2016 JMP Securities Life Sciences Conference - [at noodls] - WATERTOWN, Mass., June 15, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
06/14/16 03:13 PMTETRAPHASE PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/08/16 10:04 AMTETRAPHASE PHARMACEUTICALS INC. (NASDAQ:TTPH) Financial Condition Compared to S&P 500 - CML News
06/06/16 07:06 PMTop Earnings to Watch for: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - iStreetWire
06/03/16 09:59 AMShare Rating Focus on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - HNN
06/02/16 07:29 PMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS Estimate At $-0.51 - Investor Newswire - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Quarterly EPS Estimate At $-0.51Investor NewswireFirst Call stated that Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) can touch $9.50 in coming one year. For the next quarter, the per-share earnings target is $-0.51 and for ongoing fiscal at $-1.96. EPS target for next year is $-2.04 versus the mean ...
06/02/16 10:12 AMTarget Price and Stock Performance Rundown for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - HNN - Target Price and Stock Performance Rundown for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)HNNDuring the latest trading session, Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares traded +0.22%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/02/16 10:12 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Update & Estimates - Stock Tick Tock - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to post earnings of $-0.45 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely ...and more »
05/30/16 10:26 PMNext Weeks Broker Price Targets For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Share Trading News - Next Weeks Broker Price Targets For Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Share Trading News05/13/2016 – Tetraphase Pharmaceuticals, Inc. had its “neutral” rating reiterated by analysts at Wedbush. They now have a USD 4 price target on the stock. 04/11/2016 – BMO Capital Markets began new coverage on Tetraphase Pharmaceuticals, Inc. giving ...and more »
05/29/16 10:47 AMCDC: 1st US case of germ resistant to last resort drug - Industry experts said small, lesser-known companies with promising approaches to tackling resistant superbugs included: Entasis Therapeutics, an AstraZeneca PLC spinoff, Tetraphase Pharmaceuticals Inc (TTPH.O); and Achaogen Inc (AKAO.O). "There is no ...
05/29/16 10:47 AMWhat You Need to Know About New Antibiotic-Resistant Superbug Bacteria - Industry experts said small, lesser-known companies with promising approaches to tackling resistant superbugs included: Entasis Therapeutics, an AstraZeneca PLC spinoff, Tetraphase Pharmaceuticals Inc (TTPH.O); and Achaogen Inc (AKAO.O). He said he planned ...
05/29/16 06:00 AMNew incentives needed to develop antibiotics to fight superbugs - [Reuters - UK Focus] - Drugmakers are renewing efforts to develop medicines to fight emerging antibiotic-resistant bacteria, but creating new classes of drugs on the scale needed is unlikely to happen without new financial incentives to make the effort worth the investment, companies and industry experts said. Drugmakers on Friday acknowledged that in the absence of a new way of compensating them, it simply does not make economic sense to pour serious resources into work on new antibiotics. "The return on investment based on the current commercial model is not really commensurate with the amount of effort you have to put into it," said David Payne, who heads GlaxoSmithKline PLC (Other OTC: GLAXF - news) 's antibiotics drug group.
05/26/16 07:18 AMTarget Check and Stock Performance Recap Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Hints and News - Target Check and Stock Performance Recap Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Wall Street Hints and NewsIn recent session activity, Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) shares have traded +1.64%. Monitoring the stock price relative to moving averages may provide enhanced perspective on share performance. After a recent check, the stock has ...and more »
05/24/16 12:28 PMTetraphase Pharma (TTPH) Will Present at ASM Microbe 2016; Includes Eravacycline Phase 3 Data - Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here. Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference ...
05/23/16 07:46 AMTetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016 - [at noodls] - WATERTOWN, Mass., May 23, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 ...
05/20/16 12:13 PMAnalyst Rating Check on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Hints and News - Analyst Rating Check on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Wall Street Hints and NewsThis research may involve tracking what professional equity analysts think about the company. Currently, sell-side analysts have provided a consensus stock rating of 2.71 on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Analysts that cover ...and more »
05/20/16 12:13 PMRevenue Update on Tetraphase Pharmaceuticals Inc(NASDAQ:TTPH) - Trade Calls - Revenue Update on Tetraphase Pharmaceuticals Inc(NASDAQ:TTPH)Trade CallsTetraphase Pharmaceuticals Inc(NASDAQ:TTPH) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 4, 2016. Company reported revenue of $1.96M. Analysts estimated a revenue of $2.20M. Earnings ...
05/20/16 08:30 AMThe Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase -
05/19/16 11:50 AMMoved down in the past Week: Tetraphase Pharmaceuticals, Inc.'s (TTPH) - Is stories - Is storiesMoved down in the past Week: Tetraphase Pharmaceuticals, Inc.'s (TTPH)Is storiesTetraphase Pharmaceuticals, Inc.'s (TTPH) witnessed a loss of -0.80% in recent trading period with closing price of $ 3.71. The company's last traded volume of 0.61 million shares was above it's an average volume of 0.92 million shares. In the trailing ...Market Analyst's Price Target Overview about two Stocks: California Resources Corporation (NYSE:CRC), Linn Energy ...WsNews 4investorsall 218 news articles »
05/19/16 11:50 AMInvestors Reviewing Stocks: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , ImmunoCellular Therapeutics, Ltd ... - Street Updates - Investors Reviewing Stocks: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , ImmunoCellular Therapeutics, Ltd ...Street UpdatesOn 5/18/2016, shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) fell -0.80% in trading session and finally closed at $3.71. The company most recent volume stood at 607.75 thousand shares as compared to its average volume of 921.86 thousand ...
05/18/16 12:34 PMTetraphase Pharmaceuticals Inc. (TTPH) Jumps 12.39% on May 16 - Equities.com - Tetraphase Pharmaceuticals Inc. (TTPH) Jumps 12.39% on May 16Equities.comTetraphase Pharmaceuticals Inc. (TTPH) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 12.39% to $3.90, representing a gain of $0.43 per share. Some 999,919 shares traded hands on 5,026 trades, compared ...and more »
05/15/16 06:12 AMNeedham Reiterates Hold On Tetraphase Pharmaceuticals Inc (TTPH) As FDA Request Another Trial; Shares Tumble - Smarter Analyst - Smarter AnalystNeedham Reiterates Hold On Tetraphase Pharmaceuticals Inc (TTPH) As FDA Request Another Trial; Shares TumbleSmarter AnalystTetraphase Pharmaceuticals Inc (NASDAQ:TTPH) had a rough day today as shares fell 17%, after the antibiotic drug-maker announced that the FDA is requiring one more successful Phase 3 trial of the company's lead drug eravacycline, an antibiotic with ...Tetraphase Pharma (TTPH) Updates on Eravacycline Regulatory Path; FDA Says Additional Phase 3 Data NeededStreetInsider.comTetraphase Pharmaceuticals Inc (TTPH) is Downgraded by Gabelli & Co to Hold, Price Target at $7Market DigestTetraphase Pharmaceuticals Halted, Pending News (NASDAQ:TTPH)Sonoran Weekly ReviewWall Street Hints and News -The Post -Seeking Alphaall 18 news articles »
05/14/16 06:10 AMConsensus Rating Review for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) - Wall Street Hints and News - Consensus Rating Review for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 2.43 on shares of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a ...and more »
05/13/16 03:36 PMNordstrom and Wal-Mart fall, Shake Shack and Nvidia jump -
05/13/16 01:38 PMFriday's 10 Biggest Mid-Day Losers - ConforMIS Inc (NASDAQ: CFMS) down 51.68% - The company cut 2016 sales guidance from $84-87 million to $76-81 million and is in search for a new CEO EXCO Resources Inc (NYSE: XCO) down 36.29% - The company announced a special committee that will look for strategic alternatives for capital structure and structural liquidity improvement Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) down 18.85% - ...Full story available on Benzinga.com
05/13/16 07:36 AMTetraphase Pharmaceuticals downgraded by Gabelli & Co -
05/13/16 06:22 AMTetraphase Pharma (TTPH) Updates on Eravacycline Regulatory Path; FDA Says Additional Phase 3 Data Needed - StreetInsider.com - Tetraphase Pharma (TTPH) Updates on Eravacycline Regulatory Path; FDA Says Additional Phase 3 Data NeededStreetInsider.comTetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the regulatory path of the Company's lead candidate, eravacycline, an antibiotic with potent activity ...Tetraphase Pharmaceuticals Halted, Pending News (NASDAQ:TTPH)Sonoran Weekly ReviewTetraphase Pharmaceuticals Inc (TTPH) is Reiterated by Wedbush to Outperform, Lowers Price Target to $ 4Market DigestTetraphase Pharmaceuticals Incorporated (NASDAQ:TTPH) Shorted Shares Increased 6.92% After Market SellingThe Postall 4 news articles »
05/12/16 04:27 PMTetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status - [at noodls] - - Additional phase 3 clinical trial in cIAI planned to support NDA filing - -Phase 3 clinical trial in cUTI planned for future supplemental NDA - - Company to host conference call at 4:30 p.m. ET today ...
05/12/16 02:47 PMETF’s with exposure to Tetraphase Pharmaceuticals, Inc. : May 12, 2016 -
05/11/16 12:04 PMTETRAPHASE PHARMACEUTICALS INC Financials -
05/11/16 11:31 AMTetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/08/16 05:54 AMHealthcare Trading Stocks: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , Momenta Pharmaceuticals, Inc ... - Is stories - Healthcare Trading Stocks: Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) , Momenta Pharmaceuticals, Inc ...Is storiesTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) decreased -2.53% to $4.24 while traded 1.07 million shares on 5/6/2016. The stock price negotiated for value between $4.10 to $4.52 in recent trading session. During the past 52 weeks, the stock's price ...and more »
05/04/16 04:50 PM5:50 pm Tetraphase Pharmaceuticals misses by $0.04, misses on revs -
05/04/16 04:01 PMTetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - WATERTOWN, Mass., May 04, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant ...
05/04/16 03:09 PMTETRAPHASE PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
04/28/16 06:09 AMTetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Analyst Rating Review - The Post - Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Analyst Rating ReviewThe PostCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 3 analysts that have provided ratings for Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). 2 have rated the ...and more »
04/28/16 06:09 AMTetraphase Pharmaceuticals Inc. (TTPH) Drops 6.77% on April 26 - Equities.com - Tetraphase Pharmaceuticals Inc. (TTPH) Drops 6.77% on April 26Equities.comTetraphase Pharmaceuticals Inc. (TTPH) was one of the Russell 2000's biggest losers for Tuesday April 26 as the stock slid 6.77% to $5.51, a loss of $-0.4 per share. Starting at an opening price of $5.92 a share, the stock traded between $5.40 and $6 ...and more »
04/07/16 07:00 AMTetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) - [GlobeNewswire] - WATERTOWN, Mass., April 07, 2016-- Tetraphase Pharmaceuticals, Inc. today announced five data presentations at the 26 th European Congress of Clinical Microbiology and Infectious Diseases, taking place ...
03/25/16 02:14 PMEQUITY UPDATE: Goldberg Law PC Files Securities Class Action Lawsuit against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm - [Business Wire] - Goldberg Law PC announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. . Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, , are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline.
03/25/16 09:50 AMIMPORTANT DEADLINE REMINDER: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm - [Business Wire] - Khang & Khang LLP announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. . Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive , are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline.
03/25/16 09:00 AMDEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. and Lead Plaintiff Deadline: March 28, 2016 - [Accesswire] - NEW YORK, NY / ACCESSWIRE / March 25, 2016 / Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court ...
About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant infections. The Company is engaged in developing its product candidate, eravacycline, which is a fully synthetic tetracycline derivative, as a spectrum intravenous (IV), and an oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant Gram-negative infections. TP-271 is a fully synthetic broad-spectrum preclinical compound that the Company developed for respiratory diseases caused by bacterial biothreat pathogens. The Company created TP-271 using its chemistry technology. In its development program for TP-271, the Company has conducted a number of in vitro, toxicology and animal studies to evaluate the efficacy of TP-271 against biothreat pathogens.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TTPH
  • CUSIP:
Key Metrics:
  • Previous Close: $4.02
  • 50 Day Moving Average: $4.12
  • 200 Day Moving Average: $5.46
  • P/E Ratio: N/A
  • P/E Growth: -0.01
  • Market Cap: $147.16M
  • Current Quarter EPS Consensus Estimate: $-1.96 EPS
Additional Links:
Tetraphase Pharmaceuticals (NASDAQ:TTPH) Chart for Monday, June, 27, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha